Cerus Q3 adjusted EBITDA beats analyst estimates on higher IFC sales, platelet franchise strength
CERS•Cerus reported third-quarter adjusted EBITDA of $5.7 million, beating the $4 million analyst estimate, as product revenue rose 10% year over year. The company maintained its 2026 product revenue guidance of $229 million to $231 million.
1. Quarterly results
Cerus said third-quarter product revenue rose 10% year over year, driven by higher U.S. INTERCEPT Fibrinogen Complex sales and strength in its U.S. platelet franchise. Sales of INT200 illuminators in EMEA also supported quarterly revenue. Adjusted EBITDA was $5.7 million, compared with a $4 million analyst consensus estimate; gross margin was 52.4% and gross profit was $30.3 million.
2. Outlook and trial
Cerus maintained its full-year 2026 product revenue guidance of $229 million to $231 million and expects IFC revenue of $23 million to $25 million. It anticipates continued growth in IFC and an international INT200 rollout. The company also announced positive topline results from its Phase 3 RedeS trial for the INTERCEPT RBC system.
